Visit https://www.peervoice.com/UET860 to view the entire programme with slides. After completing “Perry Elliott, MD, FRCP - What’s New and What’s Next? Expanding Our Understanding of HCM in 2023”, participants will be able to: Discuss emerging clinical data related to the management of hypertrophic cardiomyopathy (HCM); Describe the latest updates on guideline recommendations for provision of evidence-based care for patients with HCM; and Use emerging clinical data and latest updates on guideline recommendations to manage patients with HCM.

Visit https://www.peervoice.com/RHS860 to view the entire programme with slides. After completing “Edward B. Garon, MD, MS - Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations”, participants will be able to: Identify current and anticipated strategies for managing NSCLC without actionable oncogenic driver mutations, including combination approaches with immunotherapies and other agents; and Assess the clinical relevance of safety and efficacy data from randomized clinical trials evaluating novel treatment approaches in advanced NSCLC without actionable genomic alterations.

Visit https://www.peervoice.com/JHP860 to view the entire programme with slides. After completing “Claus Vogelmeier, MD - Approaching Airway Inflammation From Another Angle: The Rationale for Targeting Type 2 Pathways in COPD”, participants will be able to: Identify current unmet needs in the achievement of goals of care in patients with chronic obstructive pulmonary disease (COPD); Describe the role of type 2 inflammation in the pathophysiology of COPD; and Evaluate emerging efficacy and safety data for the use of biologic therapies in the treatment of COPD.

Visit https://www.peervoice.com/HPG860 to view the entire programme with slides. After completing “Perry Elliott, MD, FRCP - Continuing Our Conversation in HCM: Compelling Questions and Evolving Considerations”, participants will be able to:

Visit https://www.peervoice.com/THW860 to view the entire programme with slides. After completing “Laura Obici, MD - Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (ATTR): Shared Perspectives From Patients and Providers”, participants will be able to: Identify unmet needs in the identification and diagnosis of patients with transthyretin amyloidosis (ATTR); and Apply recommended approaches to promote accurate and timely diagnosis and intervention in ATTR.

Visit https://www.peervoice.com/FQC860 to view the entire programme with slides. After completing “Wong Seng Weng, MBBS, MRCP, FAMS - Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next?”, participants will be able to: Recognise current unmet needs for patients with EGFR-mutant NSCLC who progress after multiple lines of therapy; Assess the clinical relevance of available safety and efficacy data evaluating novel therapies in patients with EGFR-mutant NSCLC who have progressed following TKI therapy and chemotherapy; and Identify evidence-based best practices for managing patients with EGFR-mutant NSCLC who have progressed following TKI therapy and chemotherapy.

Visit https://www.peervoice.com/HGF860 to view the entire programme with slides. After completing “David Planchard, MD, PhD - Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting”, participants will be able to: Explain the rationale for use of CEACAM5-directed therapies in the treatment of NSCLC; Identify recommended approaches for detection of CEACAM5 expression in patients with NSCLC; and Evaluate available efficacy and safety data from clinical trials evaluating CEACAM5-directed therapies for NSCLC.

Visit https://www.peervoice.com/RSW860 to view the entire programme with slides. After completing “Sarah Jarvis, MBE, FRCGP - Achieving Shared Goals Across the Spectrum of CKD and HF”, participants will be able to: Identify patients at risk for and with chronic kidney disease (CKD) and heart failure (HF) based on early clinical indicators to expedite diagnosis and interventions; Recognise common barriers to evidence-based implementation of SGLT2 inhibition and strategies to overcome them; and Manage patients at risk for and with CKD and HF using a collaborative multidisciplinary approach.

Visit https://www.peervoice.com/FZR860 to view the entire programme with slides. After completing “Mansoor Husain, MD - Integrating GLP-1 RAs Into Our Cardiology Care Pathways: Who, When, and Why?”, participants will be able to: Identify the current place in therapy for GLP-1 receptor agonists (RAs) within guideline-recommended treatment algorithms for type 2 diabetes mellitus (T2DM); Evaluate current efficacy and safety data related to the effects of GLP-1 RAs on glycaemia, cardiometabolic risk, and weight in patients with T2DM; and Identify patients with T2DM who would benefit from incorporation of a GLP-1 RA into their overall treatment plan.

Visit https://www.peervoice.com/GYQ860 to view the entire programme with slides. After completing “Kieran McCafferty, MB BChir, MRCP, MD (res) / Shelley Zieroth, MD, FRCPC, FHFSA (hon) - Handling Hyperkalaemia Without Compromising Care for Chronic Kidney Disease and Heart Failure”, participants will be able to: Evaluate the impact of hyperkalaemia and its implications for cardiovascular and renal protection and disease management; Apply current evidence and guidance for the use of potassium binders to enable optimisation of recommended therapies, such as renin angiotensin aldosterone system inhibition (RAASi), in patients at risk for and with heart failure (HF) and/or chronic kidney disease (CKD); and Design practical strategies for the long-term management of chronic hyperkalaemia which optimise safety, efficacy, quality of life, and overall patient outcomes.